1. Home
  2. XNET vs PRTC Comparison

XNET vs PRTC Comparison

Compare XNET & PRTC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Xunlei Limited

XNET

Xunlei Limited

HOLD

Current Price

$6.77

Market Cap

448.1M

Sector

Technology

ML Signal

HOLD

Logo PureTech Health plc

PRTC

PureTech Health plc

HOLD

Current Price

$16.91

Market Cap

386.7M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
XNET
PRTC
Founded
2003
2015
Country
China
United States
Employees
N/A
N/A
Industry
Computer Software: Prepackaged Software
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
448.1M
386.7M
IPO Year
2014
N/A

Fundamental Metrics

Financial Performance
Metric
XNET
PRTC
Price
$6.77
$16.91
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
339.1K
4.8K
Earning Date
11-13-2025
08-28-2025
Dividend Yield
N/A
N/A
EPS Growth
8740.73
N/A
EPS
20.16
0.20
Revenue
$401,918,000.00
$6,391,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$0.35
$7.87
Revenue Growth
27.19
1265.60
52 Week Low
$1.90
$13.30
52 Week High
$11.03
$23.35

Technical Indicators

Market Signals
Indicator
XNET
PRTC
Relative Strength Index (RSI) 37.04 51.09
Support Level $7.06 $16.44
Resistance Level $7.46 $17.17
Average True Range (ATR) 0.30 0.35
MACD 0.04 0.12
Stochastic Oscillator 13.58 55.29

Price Performance

Historical Comparison
XNET
PRTC

About XNET Xunlei Limited

Xunlei Ltd is a cloud-based acceleration technology company in China. The company operates a powerful internet platform in China based on cloud computing to provide users with quick and easy access to digital media content through its products and services, Xunlei Accelerator, and cloud acceleration subscription services. It is increasingly extending into mobile devices in part through potentially pre-installed acceleration products in mobile phones Xunlei has developed various value-added services to meet a fuller spectrum of its users' digital media content access and consumption needs.

About PRTC PureTech Health plc

PureTech Health PLC, together with its subsidiaries, is a clinical-stage biopharma company developing medicines to modulate the adaptive human system. The company is focused on developing and commercializing differentiated medicines for devastating diseases, including inflammatory, immunological conditions, intractable cancers, lymphatic & gastrointestinal diseases, and neurological and neuropsychological disorders, among others. Its drug development pipeline consists of Deupirfenidone (LYT-100), for the potential treatment of idiopathic pulmonary fibrosis (IPF), LYT-200, SPT-300, an oral drug for depressive disorder, SPT-320, and others. The company's operating segments include Parent Companies & Other, which derives key revenue, Wholly-Owned Programs, and Controlled Founded Entities.

Share on Social Networks: